In the latest trading session, 17.53 million Adicet Bio Inc (NASDAQ:ACET) shares changed hands as the company’s beta touched 1.98. With the company’s most recent per share price at $0.93 changing hands around $0.01 or 1.43% at last look, the market valuation stands at $76.89M. ACET’s current price is a discount, trading about -289.25% off its 52-week high of $3.62. The share price had its 52-week low at $0.81, which suggests the last value was 12.9% up since then. When we look at Adicet Bio Inc’s average trading volume, we note the 10-day average is 0.17 million shares, with the 3-month average coming to 581.57K.
Analysts gave the Adicet Bio Inc (ACET) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ACET as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Adicet Bio Inc’s EPS for the current quarter is expected to be -0.35.
Adicet Bio Inc (NASDAQ:ACET) trade information
Instantly ACET is in green as seen in intraday trades today. With action 3.45%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -3.00%, with the 5-day performance at 3.45% in the green. However, in the 30-day time frame, Adicet Bio Inc (NASDAQ:ACET) is -6.00% down. Looking at the short shares, we see there were 3.43 million shares sold at short interest cover period of 7.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is 32.5, meaning bulls need an upside of 97.14% from its recent market value. According to analyst projections, ACET’s forecast low is 27 with 38 as the target high. To hit the forecast high, the stock’s price needs a -3986.02% plunge from its current level, while the stock would need to soar -2803.23% for it to hit the projected low.
Adicet Bio Inc (ACET) estimates and forecasts
Data shows that the Adicet Bio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -28.22% over the past 6 months, a 51.40% in annual growth rate that is considerably higher than the industry average of 16.00%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.75%. The 2025 estimates are for Adicet Bio Inc earnings to increase by 51.96%, but the outlook for the next 5-year period is at 22.99% per year.
ACET Dividends
Adicet Bio Inc is expected to release its next quarterly earnings report in March.
Adicet Bio Inc (NASDAQ:ACET)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.59% of Adicet Bio Inc shares while 76.44% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.67%. There are 76.44% institutions holding the Adicet Bio Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 14.4769% of the shares, roughly 11.45 million ACET shares worth $13.85 million.
TANG CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 10.3918% or 8.22 million shares worth $9.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 2.07 shares estimated at $1.93 million under it, the former controlled 2.51% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.31% of the shares, roughly 1.08 shares worth around $1.01 million.
